Glioma tumor lysate-pulsed dendritic cell (DC) vaccination is an effective treatment modality. However, cure rates in the established tumor setting are not therapeutically significant in our preclinical models. We inferred that immunosuppressive antigen presenting cells (iAPCs) present in the tumor environment acting via the PD-1/PD-L1 mechanism mediated immune suppression in malignant glioma. To test this hypothesis in our in vivo preclinical model, mice intracranially implanted with GL261 gliomas were treated with DC vaccination +/- murine anti-PD-1 mAb (RMP1-14, Bioxcell) blockade or a CNS-penetrant small molecule inhibitor of CSF-1R (PLX-3397, Plexxikon) and overall survival was quantified. We then harvested and characterized the intratumoral cellular infiltrate and demonstrated the presence of a PD-L1+ CD11b+ CSF1r+ inhibitory antigen-presenting cell (iAPC) population. Gene expression profiles of harvested iAPCs were assessed using the novel Nanostring nCounter analysis system. We found that treatment with DC vaccination and adjuvant PD-1 mAb blockade and PLX-3397 induced a highly significant therapeutic benefit to animals bearing well-established i.c. gliomas (and the inhibition of iAPC negative regulatory function.
Author information
Authors and Affiliations
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Antonios, J., Soto, H., Orpilla, J. et al. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response. j. immunotherapy cancer 3 (Suppl 2), P393 (2015). https://doi.org/10.1186/2051-1426-3-S2-P393
Published:
DOI: https://doi.org/10.1186/2051-1426-3-S2-P393